(S1 (S (S (NP (NN AKT2)) (VP (VBZ is) (NP (NP (DT a) (JJ downstream) (NN target)) (PP (IN of) (NP (NP (JJ metabotropic) (NN glutamate) (NN receptor) (CD 1)) (PRN (-LRB- -LRB-) (NP (NN Grm1)) (-RRB- -RRB-))))))) (. .)))
(S1 (S (S (NP (PRP We)) (VP (VBD reported) (ADVP (RBR earlier)) (PP (IN on) (NP (NP (DT the) (JJ oncogenic) (NNS properties)) (PP (IN of) (NP (NN Grm1))))) (PP (IN by) (S (VP (VBG demonstrating) (SBAR (IN that) (S (NP (JJ stable) (JJ Grm1-mouse-melanocytic) (NNS clones)) (VP (VBP proliferate) (PP (IN in) (NP (NP (DT the) (NN absence)) (PP (IN of) (NP (NP (NN growth) (NN supplement)) (CC and) (NP (NN anchorage)))))) (ADVP (FW in) (FW vitro)))))))))) (. .)))
(S1 (S (S (PP (IN In) (NP (NN addition))) (, ,) (NP (DT these) (NNS clones)) (ADVP (RB also)) (VP (VBP exhibit) (NP (JJ aggressive) (JJ tumorigenic) (NNS phenotypes)) (ADVP (FW in) (FW vivo)) (PP (IN with) (NP (NP (JJ short) (NN latency)) (PP (IN in) (NP (NP (NN tumor) (NN formation)) (PP (IN in) (NP (ADJP (CC both) (ADJP (JJ immunodeficient)) (CC and) (ADJP (JJ syngeneic))) (NNS mice))))))))) (. .)))
(S1 (S (NP (PRP We)) (ADVP (RB also)) (VP (VBD detected) (NP (NP (JJ strong) (NN activation)) (PP (IN of) (NP (NN AKT))) (PP (IN in) (NP (NN allograft) (NNS tumors)))) (ADVP (RB specifically)) (PP (NP (NN AKT2)) (IN as) (NP (NP (DT the) (JJ predominant) (NN isoform)) (VP (VBN involved))))) (. .)))
(S1 (S (S (PP (IN In) (NP (NN parallel))) (, ,) (NP (PRP we)) (VP (VP (VBD assessed) (NP (JJ several) (JJ human) (NN melanoma) (NN biopsy) (NNS samples))) (CC and) (VP (VBD found) (ADVP (RB again)) (SBAR (IN that) (S (NP (NN AKT2)) (VP (VBD was) (NP (NP (DT the) (RB predominantly) (VBN activated) (NN AKT)) (PP (IN in) (NP (DT these) (JJ human) (NN melanoma) (NNS biopsies)))))))))) (. .)))
(S1 (S (S (PP (IN In) (NP (NP (NP (VBN cultured) (JJ stable) (JJ Grm1-mouse-melanocytic) (NNS clones)) (, ,) (CONJP (RB as) (RB well) (IN as)) (NP (NP (DT an) (JJ metabotropic) (NN glutamate) (NN receptor) (CD 1)) (PRN (-LRB- -LRB-) (NP (NN Grm1)) (-RRB- -RRB-)))) (VP (VBG expressing) (NP (NP (JJ human) (NN melanoma) (NN cell) (NN line)) (, ,) (NP (NN C8161)))))) (, ,) (NP (NP (NN stimulation)) (PP (IN of) (NP (NN Grm1))) (PP (IN by) (NP (PRP$ its) (NN agonist)))) (VP (VBD led) (PP (TO to) (NP (NP (DT the) (NN activation)) (PP (IN of) (NP (NN AKT))))) (, ,) (SBAR (IN while) (S (NP (NP (NN preincubation)) (PP (IN with) (NP (NN Grm1-antagonist)))) (VP (VBD abolished) (NP (JJ Grm1-agonist-induced) (NN AKT) (NN activation))))))) (. .)))
(S1 (S (S (PP (IN In) (NP (NN addition))) (, ,) (NP (NP (DT a) (NN reduction)) (PP (IN in) (NP (NP (NN tumor) (NN volume)) (PP (IN of) (NP (NNS Grm1-mouse-melanocytic-allografts)))))) (VP (VBD was) (VP (VBN detected) (PP (IN in) (NP (NP (DT the) (NN presence)) (PP (IN of) (NP (NP (JJ small) (VBG interfering) (NN AKT2) (NN RNA)) (PRN (-LRB- -LRB-) (NP (NN siAKT2)) (-RRB- -RRB-))))))))) (. .)))
(S1 (S (S (VP (VBN Taken) (ADVP (RB together)))) (, ,) (NP (DT these) (NNS results)) (VP (VBD showed) (SBAR (IN that) (S (, ,) (PP (IN in) (NN addition) (TO to) (S (NP (NP (DT the) (NN MAPK) (NN pathway)) (VP (ADVP (RB previously)) (VBN reported))) (VP (VBG being) (NP (NP (DT a) (JJ downstream) (NN target)) (PP (IN of) (NP (NN stimulated) (NN Grm1))))))) (, ,) (NP (NN AKT2)) (VP (VBZ is) (NP (NP (DT another) (JJ downstream) (NN target)) (PP (IN in) (NP (NN Grm1) (JJ mediated) (NN melanocyte) (NN transformation)))))))) (. .)))
